133 related articles for article (PubMed ID: 36928256)
1. Diffusion-weighted magnetic resonance sequence and CA125/CEA ratio can be used as add-on tools to ultrasound for the differentiation of ovarian from non-ovarian pelvic masses.
Nunes Pereira P; Françoise Derchain S; Yoshida A; Hoelz de Oliveira Barros R; Menezes Jales R; Sarian LO
PLoS One; 2023; 18(3):e0283212. PubMed ID: 36928256
[TBL] [Abstract][Full Text] [Related]
2. Role of CA125/CEA ratio and ultrasound parameters in identifying metastases to the ovaries in patients with multilocular and multilocular-solid ovarian masses.
Moro F; Pasciuto T; Djokovic D; Di Legge A; Granato V; Moruzzi MC; Mancari R; Zannoni GF; Fischerova D; Franchi D; Scambia G; Testa AC
Ultrasound Obstet Gynecol; 2019 Jan; 53(1):116-123. PubMed ID: 29978587
[TBL] [Abstract][Full Text] [Related]
3. CEA in evaluation of adnexal mass: retrospective cohort analysis and review of the literature.
Sagi-Dain L; Lavie O; Auslander R; Sagi S
Int J Biol Markers; 2015 Nov; 30(4):e394-400. PubMed ID: 26109367
[TBL] [Abstract][Full Text] [Related]
4. Differentiating stage 1 epithelial ovarian cancer from benign ovarian tumours using a combination of tumour markers HE4, CA125, and CEA and patient's age.
Kondalsamy-Chennakesavan S; Hackethal A; Bowtell D; ; Obermair A
Gynecol Oncol; 2013 Jun; 129(3):467-71. PubMed ID: 23500084
[TBL] [Abstract][Full Text] [Related]
5. Symptoms, CA125 and HE4 for the preoperative prediction of ovarian malignancy in Brazilian women with ovarian masses.
Pitta Dda R; Sarian LO; Barreta A; Campos EA; Andrade LL; Fachini AM; Campbell LM; Derchain S
BMC Cancer; 2013 Sep; 13():423. PubMed ID: 24044637
[TBL] [Abstract][Full Text] [Related]
6. Preoperative measurement of serum C-reactive protein: is it useful in the differential diagnosis of adnexal masses?
Yoshida A; Derchain SF; Pitta DR; Crozatti N; Andrade LALA; da Silva RF; Sarian LO
Int J Biol Markers; 2017 Mar; 32(1):e83-e89. PubMed ID: 27516000
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the importance of the serum levels of CA-125, CA15-3, CA-19-9, carcinoembryonic antigen and alpha fetoprotein for distinguishing benign and malignant adnexal masses and contribution of different test combinations to diagnostic accuracy.
Bozkurt M; Yumru AE; Aral I
Eur J Gynaecol Oncol; 2013; 34(6):540-4. PubMed ID: 24601047
[TBL] [Abstract][Full Text] [Related]
8. Improving the performance of IOTA simple rules: sonographic assessment of adnexal masses with resource-effective use of a magnetic resonance scoring (ADNEX MR scoring system).
Pereira PN; Sarian LO; Yoshida A; Araújo KG; Silva ACB; de Oliveira Barros RH; Jales RM; Derchain S
Abdom Radiol (NY); 2020 Oct; 45(10):3218-3229. PubMed ID: 31482379
[TBL] [Abstract][Full Text] [Related]
9. [Borderline Ovarian Tumours: CNGOF Guidelines for Clinical Practice - Value of Tumor Markers].
Nyangoh-Timoh K; Bendifallah S; Dion L; Ouldamer L; Levêque J
Gynecol Obstet Fertil Senol; 2020 Mar; 48(3):277-286. PubMed ID: 32004789
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of ascitic fluid cell block for diagnosing primary ovarian, peritoneal, and tubal cancer in patients with peritoneal carcinomatosis with ascites.
Uehara T; Yoshida H; Fukuhara M; Yoshida M; Motoi N; Sugawara S; Sone M; Arai Y; Tamura K; Uno M; Ishikawa M; Kato T
Gynecol Oncol; 2020 May; 157(2):398-404. PubMed ID: 32063274
[TBL] [Abstract][Full Text] [Related]
11. Assessment of the diagnostic value of using serum CA125 and GI-RADS system in the evaluation of adnexal masses.
Zheng H; Tie Y; Wang X; Yang Y; Wei X; Zhao X
Medicine (Baltimore); 2019 Feb; 98(7):e14577. PubMed ID: 30762809
[TBL] [Abstract][Full Text] [Related]
12. Preoperative evaluation of ovarian masses: ultrasound and biochemical screening.
Piccioni MG; Fabiani C; Fattouche V; Furano S; Melluso J; Sabelli V
Clin Exp Obstet Gynecol; 2003; 30(4):217-9. PubMed ID: 14664416
[TBL] [Abstract][Full Text] [Related]
13. Assessing CT imaging features combined with CEA and CA125 levels to identify endometriosis-associated ovarian cancer.
Li M; Tan J; Zhang Y; Ai C; Wang H; Zhang H; Jin Y; Chen Y
Abdom Radiol (NY); 2021 Jun; 46(6):2367-2375. PubMed ID: 32424610
[TBL] [Abstract][Full Text] [Related]
14. HE4 can help discriminate women with malignant ovarian
tumors only if CA125 levels are elevated.
Pitta Dda R; Sarian LO; Campos EA; Andrade LL; Sallum LF; Bragança JF; Campos Cde M; Derchain S
Int J Biol Markers; 2013; 28(4):e377-86. PubMed ID: 23828407
[TBL] [Abstract][Full Text] [Related]
15. Serum human epididymal protein 4 (HE4) as biomarker for the differentiation between epithelial ovarian cancer and ovarian metastases of gastrointestinal origin.
Stiekema A; Boldingh QJ; Korse CM; van der Noort V; Boot H; van Driel WJ; Kenter GG; Lok CA
Gynecol Oncol; 2015 Mar; 136(3):562-6. PubMed ID: 25560808
[TBL] [Abstract][Full Text] [Related]
16. HE4 as a serum biomarker for the diagnosis of pelvic masses: a prospective, multicenter study in 965 patients.
Braicu EI; Krause CL; Torsten U; Mecke H; Richter R; Hellmeyer L; Lanowska M; Müller B; Koch E; Boenneß-Zaloum J; Ames K; Chekerov R; Hasenbein K; Zimmermann M; Mangler M; Chen F; Tauber R; Sehouli J
BMC Cancer; 2022 Jul; 22(1):831. PubMed ID: 35907794
[TBL] [Abstract][Full Text] [Related]
17. Outcomes from ultrasound follow-up of small complex adnexal masses in women over 50.
Suh-Burgmann E; Hung YY; Kinney W
Am J Obstet Gynecol; 2014 Dec; 211(6):623.e1-7. PubMed ID: 25068555
[TBL] [Abstract][Full Text] [Related]
18. Is the Risk of Ovarian Malignancy Algorithm Better Than Other Tests for Predicting Ovarian Malignancy in Women with Pelvic Masses?
Yanaranop M; Anakrat V; Siricharoenthai S; Nakrangsee S; Thinkhamrop B
Gynecol Obstet Invest; 2017; 82(1):47-53. PubMed ID: 27197526
[TBL] [Abstract][Full Text] [Related]
19. A comparative study of serum alpha-beta A immunoreactive inhibin and tumor-associated antigens CA125 and CEA in ovarian cancer.
Phocas I; Sarandakou A; Sikiotis K; Rizos D; Kalambokis D; Zourlas PA
Anticancer Res; 1996; 16(6B):3827-31. PubMed ID: 9042265
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.
Karlsen MA; Sandhu N; Høgdall C; Christensen IJ; Nedergaard L; Lundvall L; Engelholm SA; Pedersen AT; Hartwell D; Lydolph M; Laursen IA; Høgdall EV
Gynecol Oncol; 2012 Nov; 127(2):379-83. PubMed ID: 22835718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
